BNO.AX : Summary for BIONOMICS FPO - Yahoo Finance

U.S. Markets close in 3 hrs 8 mins

Bionomics Limited (BNO.AX)


ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.360.00 (0.00%)
At close: 3:08PM AEDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.36
Open0.36
Bid0.00 x
Ask0.00 x
Day's Range0.36 - 0.38
52 Week Range0.23 - 0.50
Volume141,406
Avg. Volume398,843
Market Cap173.33M
BetaN/A
PE Ratio (TTM)-10.29
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Bionomics Ltd. breached its 50 day moving average in a Bullish Manner : BNO-AU : March 15, 2017
    Capital Cube8 days ago

    Bionomics Ltd. breached its 50 day moving average in a Bullish Manner : BNO-AU : March 15, 2017

    Categories: Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Bionomics Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • Bionomics Ltd. :BNO-AU: Earnings Analysis: For the six months ended December 31, 2016 : February 23, 2017
    Capital Cube28 days ago

    Bionomics Ltd. :BNO-AU: Earnings Analysis: For the six months ended December 31, 2016 : February 23, 2017

    Categories: Yahoo Finance Get free summary analysis Bionomics Ltd. reports financial results for the half-year ended December 31, 2016. We analyze the earnings along side the following peers of Bionomics Ltd. – Factor Therapeutics Limited (FTT-AU) that have also reported for this period. Highlights Summary numbers: Revenues of AUD 2.42 million, Net Earnings of AUD -9.70 million. Earnings ... Read more (Read more...)

  • PR Newswire2 months ago

    Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer's Treatment

    NEW YORK, Feb. 3, 2017 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced the completion of the first milestone in its ongoing collaboration with MSD (known as Merck & Co., Inc., Kenilworth NJ, USA in the US and Canada) to develop novel candidates for treatment of cognitive dysfunction associated with Alzheimer's disease. As part of a research collaboration and license agreement announced in June 2014 the first administration of a candidate therapy in a clinical trial triggers a US$10 million milestone payment to Bionomics.